In the third quarter, Financial Consulate Inc. initiated a position in Johnson & Johnson by purchasing 3,364 shares, representing an investment of approximately $624,000. This marks the firm's first disclosed holding in the company, as reported in its most recent Form 13F filing with the Securities and Exchange Commission. The purchase suggests growing institutional confidence in Johnson & Johnson’s diversified healthcare portfolio, which spans pharmaceuticals, medical devices and consumer health products.

Virginia Retirement Systems et al. increased its stake in Johnson & Johnson by 12.3% during the third quarter, acquiring an additional 127,100 shares to bring its total position to 1,158,903 shares. Valued at roughly $214.9 million at quarter end, this holding now accounts for 1.4% of the fund’s total assets and ranks as its ninth largest equity position. This move underscores the fund’s strategic allocation toward large-cap, dividend-paying healthcare names.

For the quarter ended August 30, Johnson & Johnson reported earnings per share of $2.26 on revenues of $24.02 billion, delivering a net margin of 27.26% and a return on equity of 32.73%. The company declared a quarterly dividend of $1.30 per share, payable March 10 to shareholders of record as of February 24. This distribution equates to an annualized payout of $5.20 per share and reflects a dividend payout ratio of approximately 50.2%.

Following recent research notes, the consensus among 27 analysts is a "Moderate Buy" rating on Johnson & Johnson, with four assigning a Strong Buy, fourteen a Buy and nine a Hold. The average price target stands at $211.25. Notable actions include upgrades from UBS, Daiwa Capital Markets and Guggenheim, as well as reaffirmations from Cowen and BMO Capital Markets, reflecting optimism about the company’s earnings growth prospects and stable free cash flow generation.